Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Audrey Gabelle

Showing results (51-60 of 171) with videos related to

Pageof 18
Sort By:
Clinical Chemistry|September 1, 2023
Head-to-Head Comparison of Two Plasma Phospho-tau Assays in Predicting Conversion of Mild Cognitive Impairment to DementiaSylvain Lehmann, Susanna Schraen-Maschke, Jean-Sébastien Vidal, et al.
International Journal of Molecular Sciences|December 23, 2023
Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer's Disease ContinuumSylvain Lehmann, Susanna Schraen-Maschke, Jean-Sébastien Vidal, et al.
Maturitas|October 22, 2021
Cross-sectional and longitudinal interaction effects of physical activity and APOE-ε4 on white matter integrity in older adults: The MAPT studyJérémy Raffin, Yves Rolland, Lingxiao He, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 3, 2023
Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal functionSylvain Lehmann, Susanna Schraen-Maschke, Jean-Sébastien Vidal, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 16, 2014
Plasma β-amyloid 40 levels are positively associated with mortality risks in the elderlyAudrey Gabelle, Susanna Schraen, Laure-Anne Gutierrez, et al.
The Journal of Prevention of Alzheimer'S Disease|April 20, 2025
A six-year risk assessment for dementia and Alzheimer's disease in the general population through immunoprecipitation-mass spectrometry plasma amyloid quantificationGermain U Busto, Christophe Hirtz, Isabelle Carriere, et al.
Journal of Personalized Medicine|November 27, 2021
Characteristics of Bipolar Patients with Cognitive Impairment of Suspected Neurodegenerative Origin: A Multicenter CohortEsteban Munoz Musat, Emeline Marlinge, Mélanie Leroy, et al.
Journal of Proteome Research|January 9, 2016
Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure HeterogeneityNicolas R Barthélemy, François Fenaille, Christophe Hirtz, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 31, 2016
Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratiosCecilia Marelli, Laure-Anne Gutierrez, Nicolas Menjot de Champfleur, et al.
Journal of Alzheimer'S Disease : JAD|March 1, 2016
Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy BodiesNicolas R Barthélemy, Audrey Gabelle, Christophe Hirtz, et al.
Pageof 18

Showing results (51-60 of 171) with videos related to

Sort By:
Pageof 18
Clinical Chemistry|September 1, 2023
Head-to-Head Comparison of Two Plasma Phospho-tau Assays in Predicting Conversion of Mild Cognitive Impairment to DementiaSylvain Lehmann, Susanna Schraen-Maschke, Jean-Sébastien Vidal, et al.
International Journal of Molecular Sciences|December 23, 2023
Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer's Disease ContinuumSylvain Lehmann, Susanna Schraen-Maschke, Jean-Sébastien Vidal, et al.
Maturitas|October 22, 2021
Cross-sectional and longitudinal interaction effects of physical activity and APOE-ε4 on white matter integrity in older adults: The MAPT studyJérémy Raffin, Yves Rolland, Lingxiao He, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 3, 2023
Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal functionSylvain Lehmann, Susanna Schraen-Maschke, Jean-Sébastien Vidal, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 16, 2014
Plasma β-amyloid 40 levels are positively associated with mortality risks in the elderlyAudrey Gabelle, Susanna Schraen, Laure-Anne Gutierrez, et al.
The Journal of Prevention of Alzheimer'S Disease|April 20, 2025
A six-year risk assessment for dementia and Alzheimer's disease in the general population through immunoprecipitation-mass spectrometry plasma amyloid quantificationGermain U Busto, Christophe Hirtz, Isabelle Carriere, et al.
Journal of Personalized Medicine|November 27, 2021
Characteristics of Bipolar Patients with Cognitive Impairment of Suspected Neurodegenerative Origin: A Multicenter CohortEsteban Munoz Musat, Emeline Marlinge, Mélanie Leroy, et al.
Journal of Proteome Research|January 9, 2016
Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure HeterogeneityNicolas R Barthélemy, François Fenaille, Christophe Hirtz, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 31, 2016
Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratiosCecilia Marelli, Laure-Anne Gutierrez, Nicolas Menjot de Champfleur, et al.
Journal of Alzheimer'S Disease : JAD|March 1, 2016
Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy BodiesNicolas R Barthélemy, Audrey Gabelle, Christophe Hirtz, et al.
Pageof 18